These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9013982)

  • 1. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.
    Tempero RM; Hollingsworth MA; Burdick MD; Finch AM; Taylor SM; Vogen SM; Morgan EL; Sanderson SD
    J Immunol; 1997 Feb; 158(3):1377-82. PubMed ID: 9013982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.
    Ulrich JT; Cieplak W; Paczkowski NJ; Taylor SM; Sanderson SD
    J Immunol; 2000 May; 164(10):5492-8. PubMed ID: 10799917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
    Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
    J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant.
    Sanderson SD; Cheruku SR; Padmanilayam MP; Vennerstrom JL; Thiele GM; Palmatier MI; Bevins RA
    Int Immunopharmacol; 2003 Jan; 3(1):137-46. PubMed ID: 12538044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
    Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
    Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.
    Hegde GV; Meyers-Clark E; Joshi SS; Sanderson SD
    Int Immunopharmacol; 2008 Jun; 8(6):819-27. PubMed ID: 18442785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformationally biased analogs of human C5a mediate changes in vascular permeability.
    Kawatsu R; Sanderson SD; Blanco I; Kendall N; Finch AM; Taylor SM; Colcher D
    J Pharmacol Exp Ther; 1996 Jul; 278(1):432-40. PubMed ID: 8764379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.
    Krikorian D; Panou-Pomonis E; Voitharou C; Sakarellos C; Sakarellos-Daitsiotis M
    Bioconjug Chem; 2005; 16(4):812-9. PubMed ID: 16029022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
    J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
    Grinstead JS; Schuman JT; Campbell AP
    Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
    Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
    Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.
    Morgan EL; Morgan BN; Stein EA; Vitrs EL; Thoman ML; Sanderson SD; Phillips JA
    Vaccine; 2009 Dec; 28(2):463-9. PubMed ID: 19836478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke.
    Floreani AA; Heires AJ; Welniak LA; Miller-Lindholm A; Clark-Pierce L; Rennard SI; Morgan EL; Sanderson SD
    J Immunol; 1998 May; 160(10):5073-81. PubMed ID: 9590258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle.
    Kim DY; Martin CB; Lee SN; Martin BK
    Cancer Immunol Immunother; 2005 Oct; 54(10):1026-37. PubMed ID: 15868168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
    Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
    Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.